Nonlinear relationship between viral load and TCT in single/multiple HPV52 infection.


Journal

Virology journal
ISSN: 1743-422X
Titre abrégé: Virol J
Pays: England
ID NLM: 101231645

Informations de publication

Date de publication:
23 Apr 2024
Historique:
received: 19 11 2023
accepted: 02 04 2024
medline: 24 4 2024
pubmed: 24 4 2024
entrez: 23 4 2024
Statut: epublish

Résumé

To determine the correlation between HPV (human papillomavirus) 52 viral load, multiple infections and ThinPrep cytology test (TCT), to inform clinical management of HPV52-positive women after cervical cancer screening. A total of 1,882 female patients who had positive quantitative HPV tests at Yuebei People's Hospital from January 2020 to December 2022, of whom 533 tested positive for HPV52. We excluded patients who combined HPV16 and/or HPV 18 positivity and whom HPV52 viral load could not be calculated. The final enrollment was 488 patients, including 400 NILM, 48 ASC-US, 28 LSIL and 12 HSIL. The HPV test is a quantitative multiplexed fluorescent PCR assay that provides both HPV genotyping and viral load. In our study, there were differences in the median distribution of viral loads among various cytological class categories. The risk of TCT results (LSIL or worse) was increased with the increase of HPV52 viral load, for every LOG unit increase in HPV52 viral load, the risk increased by 26.6%. More importantly, we found a nonlinear relationship between HPV52 viral load and TCT results (LSIL or worse) in both single and multiple infections. When the viral load reaches a threshold, the risk of abnormal cytological results increases significantly. HPV52 viral load is an independent risk factor for TCT results (LSIL or worse). The relationship between HPV52 viral load and TCT results (LSIL or worse) is not linear. Viral load may be used as a triage indicator for HPV52-positive patients, thus improving the post-screening clinical management of HPV52-positive women.

Identifiants

pubmed: 38654353
doi: 10.1186/s12985-024-02356-4
pii: 10.1186/s12985-024-02356-4
doi:

Substances chimiques

DNA, Viral 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

90

Informations de copyright

© 2024. The Author(s).

Références

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49.
doi: 10.3322/caac.21660 pubmed: 33538338
Humans IWGotEoCRt: Biological agents. IARC Monogr Eval Carcinog Risks Hum 2012, 100(Pt B):1–441.
Dizon DS, Krilov L, Cohen E, Gangadhar T, Ganz PA, Hensing TA, Hunger S, Krishnamurthi SS, Lassman AB, Markham MJ, et al. Clinical cancer advances 2016: annual report on progress against cancer from the american society of clinical oncology. J Clin Oncol. 2016;34(9):987–1011.
doi: 10.1200/JCO.2015.65.8427 pubmed: 26846975
Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture Eur J Cancer. 2001;37(Suppl 8):S4–66.
doi: 10.1016/S0959-8049(01)00267-2 pubmed: 11602373
Arbyn M, Castellsague X, de Sanjose S, Bruni L, Saraiya M, Bray F, Ferlay J. Worldwide burden of cervical cancer in 2008. Ann Oncol. 2011;22(12):2675–86.
doi: 10.1093/annonc/mdr015 pubmed: 21471563
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
doi: 10.3322/caac.21492 pubmed: 30207593
Luo H, Belinson JL, Du H, Liu Z, Zhang L, Wang C, Qu X, Pretorius RG, Wu R. Evaluation of viral load as a triage strategy with primary high-risk human papillomavirus cervical cancer screening. J Low Genit Tract Dis. 2017;21(1):12–6.
doi: 10.1097/LGT.0000000000000277 pubmed: 27851695
Dong L, Wang MZ, Zhao XL, Feng RM, Hu SY, Zhang Q, Smith JS, Qiao YL, Zhao FH. Human papillomavirus viral load as a useful triage tool for non-16/18 high-risk human papillomavirus positive women: A prospective screening cohort study. Gynecol Oncol. 2018;148(1):103–10.
doi: 10.1016/j.ygyno.2017.11.016 pubmed: 29169614
Adcock R, Cuzick J, Hunt WC, McDonald RM, Wheeler CM. New Mexico HPVPRSC: Role of HPV Genotype, Multiple Infections, and Viral Load on the Risk of High-Grade Cervical Neoplasia. Cancer Epidemiol Biomarkers Prev. 2019;28(11):1816–24.
doi: 10.1158/1055-9965.EPI-19-0239 pubmed: 31488417 pmcid: 8394698
Schmitt M, Depuydt C, Benoy I, Bogers J, Antoine J, Arbyn M, Pawlita M, Group VS: Multiple human papillomavirus infections with high viral loads are associated with cervical lesions but do not differentiate grades of cervical abnormalities. J Clin Microbiol 2013, 51(5):1458-1464.
Song F, Yan P, Huang X, Wang C, Du H, Qu X, Wu R. Roles of extended human papillomavirus genotyping and multiple infections in early detection of cervical precancer and cancer and HPV vaccination. BMC Cancer. 2022;22(1):42.
doi: 10.1186/s12885-021-09126-3 pubmed: 34991494 pmcid: 8734293
Zhao X, Zhao S, Hu S, Zhao K, Zhang Q, Zhang X, Pan Q, Zhao F. Role of human papillomavirus DNA load in predicting the long-term risk of cervical cancer: a 15-year prospective cohort study in China. J Infect Dis. 2019;219(2):215–22.
doi: 10.1093/infdis/jiy507 pubmed: 31067317
Martinelli M, Giubbi C, Saderi L, Musumeci R, Perdoni F, Leone BE, Fruscio R, Landoni F, Piana A, Sotgiu Get al: Evaluation of Human Papilloma Virus (HPV) Genotyping and Viral Load Determination as Diagnostic Biomarkers of Cervical Cancer Risk. Int J Mol Sci. 2023;24(2):1320.
Malagon T, Louvanto K, Ramanakumar AV, Koushik A, Coutlee F, Franco EL. Biomarkers of Cervical Cancer Risk Study T: Viral load of human papillomavirus types 16/18/31/33/45 as a predictor of cervical intraepithelial neoplasia and cancer by age. Gynecol Oncol. 2019;155(2):245–53.
doi: 10.1016/j.ygyno.2019.09.010 pubmed: 31604665
Wang W, Zhang XH, Li M, Hao CH, Zhao ZM, Liang HP. Association between viral loads of different oncogenic human papillomavirus types and the degree of cervical lesions in the progression of cervical Cancer. Clin Chim Acta. 2018;483:249–55.
doi: 10.1016/j.cca.2018.05.016 pubmed: 29752912
Torres-Ibarra L, Cuzick J, Lorincz AT, Spiegelman D, Lazcano-Ponce E, Franco EL, Moscicki AB, Mahmud SM, Wheeler CM, Rivera-Paredez B, et al. Comparison of HPV-16 and HPV-18 Genotyping and Cytological Testing as Triage Testing Within Human Papillomavirus-Based Screening in Mexico. JAMA Netw Open. 2019;2(11): e1915781.
doi: 10.1001/jamanetworkopen.2019.15781 pubmed: 31747033 pmcid: 6902808
Crow JM. HPV: The global burden. Nature. 2012;488(7413):S2–3.
doi: 10.1038/488S2a pubmed: 22932437
Bao YP, Li N, Smith JS, Qiao YL. members A: Human papillomavirus type distribution in women from Asia: a meta-analysis. Int J Gynecol Cancer. 2008;18(1):71–9.
doi: 10.1111/j.1525-1438.2007.00959.x pubmed: 17466054
Huang W, Xu H, Hu H, Zhang D, Liu Y, Guo Y, Xiao F, Chen W, Ma Z. The prevalence of human papillomavirus among women in northern Guangdong Province of China. Sci Rep. 2022;12(1):13353.
doi: 10.1038/s41598-022-17632-y pubmed: 35922661 pmcid: 9349279
Yang X, Li Y, Tang Y, Li Z, Wang S, Luo X, He T, Yin A, Luo M. Cervical HPV infection in Guangzhou, China: an epidemiological study of 198,111 women from 2015 to 2021. Emerg Microbes Infect. 2023;12(1): e2176009.
doi: 10.1080/22221751.2023.2176009 pubmed: 36744409 pmcid: 9936994
Oyervides-Munoz MA, Perez-Maya AA, Sanchez-Dominguez CN, Berlanga-Garza A, Antonio-Macedo M, Valdez-Chapa LD, Cerda-Flores RM, Trevino V, Barrera-Saldana HA, Garza-Rodriguez ML: Multiple HPV Infections and Viral Load Association in Persistent Cervical Lesions in Mexican Women. Viruses. 2020;12(4):380.
Liu Y, Xu C, Pan J, Sun C, Zhou H, Meng Y. Significance of the viral load of high-risk HPV in the diagnosis and prediction of cervical lesions: a retrospective study. BMC Womens Health. 2021;21(1):353.
doi: 10.1186/s12905-021-01493-0 pubmed: 34625069 pmcid: 8501737
Tao X, Austin RM, Yu T, Zhong F, Zhou X, Cong Q, Sui L, Zhao C. Risk stratification for cervical neoplasia using extended high-risk HPV genotyping in women with ASC-US cytology: A large retrospective study from China. Cancer Cytopathol. 2022;130(4):248–58.
doi: 10.1002/cncy.22536 pubmed: 34874615
Wu Z, Qin Y, Yu L, Lin C, Wang H, Cui J, Liu B, Liao Y, Warren D, Zhang X, et al. Association between human papillomavirus (HPV) 16, HPV18, and other HR-HPV viral load and the histological classification of cervical lesions: Results from a large-scale cross-sectional study. J Med Virol. 2017;89(3):535–41.
doi: 10.1002/jmv.24645 pubmed: 27464021
Segondy M, Ngou J, Kelly H, Omar T, Goumbri-Lompo O, Doutre S, Mayaud P, Didelot MN. Diagnostic value of human papillomavirus (HPV) 16 and HPV18 viral loads for the detection of high-grade cervical intraepithelial neoplasia (CIN2+) in a cohort of African women living with HIV. J Clin Virol. 2018;99–100:79–83.
doi: 10.1016/j.jcv.2018.01.006 pubmed: 29353074
Li M, Du X, Lu M, Zhang W, Sun Z, Li L, Ye M, Fan W, Jiang S, Liu A, et al. Prevalence characteristics of single and multiple HPV infections in women with cervical cancer and precancerous lesions in Beijing. China J Med Virol. 2019;91(3):473–81.
doi: 10.1002/jmv.25331 pubmed: 30281807
Bernard HU, Burk RD, Chen Z, van Doorslaer K. zur Hausen H, de Villiers EM: Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology. 2010;401(1):70–9.
doi: 10.1016/j.virol.2010.02.002 pubmed: 20206957
Constandinou-Williams C, Collins SI, Roberts S, Young LS, Woodman CB, Murray PG. Is human papillomavirus viral load a clinically useful predictive marker? A longitudinal study. Cancer Epidemiol Biomarkers Prev. 2010;19(3):832–7.
doi: 10.1158/1055-9965.EPI-09-0838 pubmed: 20200441 pmcid: 2837003
Pett M, Coleman N. Integration of high-risk human papillomavirus: a key event in cervical carcinogenesis? J Pathol. 2007;212(4):356–67.
doi: 10.1002/path.2192 pubmed: 17573670
Salazar KL, Zhou HS, Xu J, Peterson LE, Schwartz MR, Mody DR, Ge Y. Multiple human papilloma virus infections and their impact on the development of high-risk cervical lesions. Acta Cytol. 2015;59(5):391–8.
doi: 10.1159/000442512 pubmed: 26674365

Auteurs

Bingbing Ma (B)

Department of Gynecology, Yuebei People's Hospital affiliated to Shantou University Medical College, Shaoguan, China.

Jie Zhou (J)

Department of Gynecology, Yuebei People's Hospital affiliated to Shantou University Medical College, Shaoguan, China.

Weijuan Zhou (W)

Department of Gynecology, Yuebei People's Hospital affiliated to Shantou University Medical College, Shaoguan, China.

Zhanzhong Ma (Z)

Reproductive Medicine Center, Yuebei People's Hospital Affiliated to Shantou University Medical College, Shaoguan, China.

Juan Chen (J)

Department of Gynecology, Yuebei People's Hospital affiliated to Shantou University Medical College, Shaoguan, China.

Hongbo Hu (H)

Department of Gynecology, Yuebei People's Hospital affiliated to Shantou University Medical College, Shaoguan, China. KAY0401@126.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH